Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9

Autor: Stine Braendegaard Winther, Pia Österlund, Åke Berglund, Bengt Glimelius, Camilla Qvortrup, Halfdan Sorbye, Per Pfeiffer, on behalf of the Academy of Geriatric Cancer Research (AgeCare)

Publikováno v: BMC Cancer, Vol 17, Iss 1, Pp 1-7 (2017)

Abstract Background Metastatic colorectal cancer (mCRC) is a disease of older age, but there is a relative lack of knowledge about effects of chemotherapy in older patients as they are under-represented in clinical trials. Little data can guide wheth

Externí odkaz: https://doaj.org/article/99c67e463c064c20bf3675724a4d4f49

S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma

Autor: Per Pfeiffer, K R Schønnemann, Stine Braendegaard Winther, Mathilde Weisz Ejlsmark, Merete Krogh, Jon Kroll Bjerregaard, Helle Anita Jensen

Publikováno v: Winther, S B, Bjerregaard, J K, Schonnemann, K R, Ejlsmark, M W, Krogh, M, Jensen, H A & Pfeiffer, P 2018, ' S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma ', Cancer Chemotherapy and Pharmacology, vol. 81, no. 3, pp. 573–578 . https://doi.org/10.1007/s00280-018-3528-5

PURPOSE: Gemcitabine has been standard of care in advanced pancreatic adenocarcinomas (PC) for almost two decades. Randomized, primarily Japanese, studies have shown promising efficacy when combined with S-1 (GemS-1); however, no data are published i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9970c5b1ee7299ad820c5800d2fedc51
https://doi.org/10.1007/s00280-018-3528-5

Early response evaluation and CEA response in patients treated in a Danish randomized study comparing trifluridine/tipiracil (TAS-102) with or without bevazicumab in patients with chemorefractory metastatic colorectal cancer (mCRC)

Autor: L. Noergaard Petersen, Camilla Qvortrup, L. Maltha, D. Zitnjak, Sören Möller, Per Pfeiffer, Karina Gravgaard Thomsen, F. Hejlesen, Stine Braendegaard Winther, Mette Karen Yilmaz, Merete Krogh

Publikováno v: Qvortrup, C, Yilmaz, M, Möller, S, Zitnjak, D, Maltha, L, Krogh, M, Petersen, L N, Hejlesen, F, Winther, S B, Thomsen, K G & Pfeiffer, P 2019, ' Early response evaluation and CEA response in patients treated in a Danish randomized study comparing trifluridine/tipiracil (TAS-102) with or without bevazicumab in patients with chemorefractory metastatic colorectal cancer (mCRC) ', Annals of Oncology, vol. 30, no. Suppl. 5, 617P, pp. v233-v233 . https://doi.org/10.1093/annonc/mdz246.094
Qvortrup, C, Yilmaz, M, Moller, S, Zitnjak, D, Maltha, L, Krogh, M, Petersen, L N, Hejlesen, F, Winther, S B, Thomsen, K G & Pfeiffer, P 2019, ' Early response evaluation and CEA response in patients treated in a Danish randomized study comparing trifluridine/tipiracil (TAS-102) with or without bevazicumab in patients with chemorefractory metastatic colorectal cancer (mCRC) ', Annals of Oncology, vol. 30, no. Suppl. 5, 617P, pp. 233 . https://doi.org/10.1093/annonc/mdz246.094

Background Trifluridine/tipiracil (FTD/TPI, also known as TAS-102) prolongs OS in patients with chemorefractory mCRC. Inspired by the results of C-TASK FORCE (Kuboki 2017), we designed an investigator-initiated randomized trial in the last setting in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f774cd55b962c1d1f976320ced85d80
https://vbn.aau.dk/da/publications/bf16c700-be1e-48d2-b5cf-77d3acc4e905

Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9):a randomised, open-label phase 2 trial

Autor: Halfdan Sorbye, Jesper Ryg, Bengt Glimelius, Åke Berglund, Laurids Østergaard Poulsen, Carl Henrik Shah, Gabor Liposits, Eva Hofsli, Stine Braendegaard Winther, Camilla Qvortrup, Per Pfeiffer, Pia Österlund, Halla Skuladottir

Publikováno v: Winther, S B, Liposits, G, Skuladottir, H, Hofsli, E, Shah, C H, Poulsen, L Ø, Ryg, J, Osterlund, P, Berglund, Å, Qvortrup, C, Glimelius, B, Sorbye, H & Pfeiffer, P 2019, ' Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9) : a randomised, open-label phase 2 trial ', The Lancet Gastroenterology and Hepatology, vol. 4, no. 5, pp. 376-388 . https://doi.org/10.1016/S2468-1253(19)30041-X
Winther, S B, Liposits, G, Skuladottir, H, Hofsli, E, Shah, C-H, Poulsen, L Ø, Ryg, J, Osterlund, P, Berglund, Å, Qvortrup, C, Glimelius, B, Sorbye, H & Pfeiffer, P 2019, ' Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9) : a randomised, open-label phase 2 trial ', The Lancet Gastroenterology & Hepatology, vol. 4, no. 5, pp. 376-388 . https://doi.org/10.1016/S2468-1253(19)30041-X

Background: Older or vulnerable patients with metastatic colorectal cancer are seldom included in randomised trials. The multicentre NORDIC9 trial evaluated reduced-dose combination chemotherapy compared with full-dose monotherapy in older, vulnerabl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cab0f3e0a6eb85de94e3ecfd4fc1adfa
https://portal.findresearcher.sdu.dk/da/publications/4a0bf36a-aa09-4a15-827f-933c4d2d5f1a

Randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer:Nordic 8 results

Autor: Christian Kersten, Bengt Glimelius, Halfdan Sorbye, Per Pfeiffer, Åke Berglund, Kirsten Vistisen, Mette Karen Yilmaz, Stine Braendegaard Winther, Gabor Liposits, C. Qvortrup

Publikováno v: Pfeiffer, P, Glimelius, B, Winther, S, Qvortrup, C, Yilmaz, M, Berglund, A, Vistisen, K, Kersten, C, Liposits, G & Sorbye, H 2019, ' Randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer : Nordic 8 results ', Annals of Oncology, vol. 30, no. Suppl. 4, mdz154.014, pp. iv131-iv131 . https://doi.org/10.1093/annonc/mdz154.014
Pfeiffer, P, Glimelius, B, Winther, S, Qvortrup, C, Yilmaz, M, Berglund, À, Vistisen, K, Kersten, C, Liposits, G & Sorbye, H 2019, ' Randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer : Nordic 8 results ', Annals of Oncology, vol. 30, no. Suppl. 4, O 015, pp. iv131 . https://doi.org/10.1093/annonc/mdz154.014

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea65c54ac7e2f5aa21959ed2d76a6d62
https://vbn.aau.dk/da/publications/10495a3c-9b21-44d9-9628-d03005f930b3